Czech National Bank Purchases 1,091 Shares of Insulet Corporation $PODD

Key Points

• The Czech National Bank increased its holdings in Insulet Corporation (NASDAQ:PODD) by 6.8%, resulting in ownership of 17,202 shares valued at approximately $5,405,000.
• Analysts have a generally positive outlook on Insulet, with target prices ranging from $300.00 to $415.00, highlighting a consensus "Moderate Buy" rating.
• Insulet reported a significant earnings beat, with $1.17 EPS for the last quarter, surpassing estimates and indicating a 32.9% year-over-year revenue growth.

Czech National Bank increased its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 6.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,202 shares of the medical instruments supplier's stock after buying an additional 1,091 shares during the quarter. Czech National Bank's holdings in Insulet were worth $5,405,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Larson Financial Group LLC boosted its holdings in Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after acquiring an additional 81 shares during the last quarter. Zions Bancorporation National Association UT purchased a new position in shares of Insulet in the 1st quarter worth approximately $26,000. SouthState Corp grew its holdings in shares of Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock valued at $28,000 after acquiring an additional 76 shares in the last quarter. Ramirez Asset Management Inc. purchased a new stake in shares of Insulet during the first quarter valued at approximately $53,000. Finally, NewEdge Advisors LLC lifted its holdings in Insulet by 44.8% during the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier's stock worth $54,000 after acquiring an additional 64 shares during the period.

Insulet Stock Performance

Shares of PODD traded up $4.28 during trading hours on Monday, hitting $335.12. The company's stock had a trading volume of 431,486 shares, compared to its average volume of 593,672. The business has a 50 day simple moving average of $316.00 and a two-hundred day simple moving average of $295.09. Insulet Corporation has a 52-week low of $225.37 and a 52-week high of $353.50. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The company has a market cap of $23.59 billion, a price-to-earnings ratio of 101.86, a PEG ratio of 2.75 and a beta of 1.36.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. During the same period in the prior year, the company posted $0.55 EPS. Insulet's revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

PODD has been the subject of a number of recent analyst reports. Truist Financial initiated coverage on Insulet in a research note on Monday, June 16th. They issued a "buy" rating and a $365.00 price objective for the company. Piper Sandler boosted their price target on shares of Insulet from $320.00 to $360.00 and gave the stock an "overweight" rating in a report on Tuesday, September 16th. Morgan Stanley restated an "overweight" rating on shares of Insulet in a research report on Thursday, August 7th. Jefferies Financial Group restated a "buy" rating on shares of Insulet in a report on Thursday, August 7th. Finally, Barclays lifted their price objective on shares of Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 21st. Sixteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $343.06.

Insider Buying and Selling at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of the business's stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Prem Singh sold 687 shares of the firm's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.